Cingulate Inc. (NASDAQ:CINGW) Short Interest Down 36.0% in July

Cingulate Inc. (NASDAQ:CINGW) was the recipient of a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 735 shares, a decline of 36.0% from the July 15th total of 1,149 shares. Based on an average daily trading volume, of 11,063 shares, the short-interest ratio is currently 0.1 days.

Cingulate Price Performance

Shares of CINGW traded down $0.00 during trading on Tuesday, reaching $0.01. 200 shares of the company traded hands, compared to its average volume of 35,230. The stock has a 50-day simple moving average of $0.02 and a 200-day simple moving average of $0.03. Cingulate has a twelve month low of $0.01 and a twelve month high of $0.12.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.